Seysara

Quick links to important sections

Seysara

Selected form

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Seysara

Property Description
Active ingredient Sarecycline Hydrochloride
Form Film-coated tablet (Oral preparation)
Pharmacological class Tetracycline-class antibiotic
Common use Systemic treatment for specific inflammatory skin conditions
Origin Semi-synthetic derivative of tetracycline

What is Seysara and its Drug Classification?

Seysara is a prescription-only oral medication containing the active component sarecycline hydrochloride. It is formally classified as a tetracycline-class drug, which is a group of anti-infective agents that function systemically to address susceptible bacterial activity.

Sarecycline is distinguished as a semi-synthetic derivative of tetracycline, establishing its origin as chemically modified from a naturally derived base. A key differentiating feature is that Seysara is for use in patients 9 years of age and older, reflecting its specific clinical target population. It is characterized as a narrow-spectrum tetracycline derivative, meaning its antibacterial effect is highly focused compared to older, broader agents like doxycycline or minocycline.

The Unique Form and General Purpose of Seysara

The medicine is supplied as a single-ingredient product and is conveniently manufactured as a film-coated tablet for oral administration, distinguishing it from topical treatments. The composition consists solely of the active ingredient combined with necessary pharmaceutical excipients.

The general purpose of this medication is to provide highly focused antibacterial activity to help manage inflammatory skin conditions associated with bacterial growth. Seysara is clinically recognized for its targeted action against Cutibacterium acnes, a key organism involved in the condition. By reducing the overall bacterial load that drives an inflammatory response, this decrease in bacterial presence and subsequent reduction in associated inflammation constitutes the primary benefit the medication is engineered to deliver.

What side effects are possible with Seysara?

Possible Side Effects and Safety Information

Official regulatory documents classify the safety profile of Seysara (sarecycline) by frequency and system-organ class, highlighting key adverse reactions and mandatory safety restrictions.


Adverse Reaction Scope

Category Official Regulatory Documentation
Key adverse reaction categories Frequency-classified reactions; System-organ class effects; Serious and Clinically Significant Adverse Reactions.
Frequency classification Common (ge 1%): Nausea, Headache, Vomiting, Abdominal pain, Diarrhea. Uncommon (ge 0.1%): Nasopharyngitis, Increased liver enzymes (ALT, AST).
System-organ classes involved Gastrointestinal Disorders (e.g., Nausea, Diarrhea); Nervous System Disorders (e.g., Headache, Dizziness); Skin and Subcutaneous Tissue Disorders (e.g., Photosensitivity).
Serious adverse reactions Intracranial Hypertension (increased pressure in the skull); Severe Hypersensitivity Reactions (e.g., Anaphylaxis, DRESS); Clostridioides difficile-associated diarrhea (CDAD); Anti-anabolic effect (elevated BUN/azotemia).
Population-specific safety considerations Pregnancy: Contraindicated due to risk of fetal harm, including inhibition of bone growth and permanent tooth discoloration. Pediatrics: Risk of permanent tooth discoloration during tooth development; use is approved for patients 9 years of age and older.
Exposure-related patterns Photosensitivity (exaggerated sunburn reaction) is a class warning associated with sun exposure. CDAD may occur during or after the completion of treatment.
Safety-related restrictions Contraindicated in individuals with hypersensitivity to any tetracycline-class drug. Contraindicated for use with isotretinoin due to the potential for additive risk of Intracranial Hypertension.

Regulatory Safety Summary

  • The drug belongs to the tetracycline class, making it subject to class warnings regarding phototoxicity and the risk of esophageal irritation/ulceration.
  • Official labeling defines specific high-level constraints, including absolute prohibitions during pregnancy and concurrent use with isotretinoin.
  • Population-specific warnings emphasize the potential for permanent tooth discoloration during periods of tooth development and the need for caution in patients with renal or hepatic impairment.

The official safety information establishes a structured framework by classifying adverse reactions based on their frequency and physiological impact, clearly outlining severe, low-frequency risks, and defining specific contraindications and safety constraints for key patient populations.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Seysara Overdose scope Regulator-Documented Statement
Documented overdose presentations None explicitly detailed in the official OVERDOSAGE section of the prescribing information.
Physiological systems affected (as stated in label) Not explicitly stated in the official OVERDOSAGE section.
Dose-related or exposure-related factors (if applicable) Not explicitly stated in the official OVERDOSAGE section.
Population-specific overdose notes (if applicable) None explicitly detailed in the official OVERDOSAGE section for specific populations.
Emergency-response statements (as written in official documents) Discontinue medication upon overdosage. Treat symptomatically. Institute supportive measures.
When immediate medical help is required (label-derived phrasing only) Get medical help right away, call 911, or contact a Poison Control center at 1-800-222-1222.

Overdose classifications (high-level) Regulator-Documented Statement
Severity classification (as defined in official documents) Not formally classified in the official OVERDOSAGE section.
Regulatory basis (EMA / FDA / etc.) FDA Prescribing Information; NIH MedlinePlus Drug Information.
Overdose-context constraints (as defined in official documents) No specific antidote is described; management must be symptomatic and supportive.

Resulting overdose structure

Official overdose statements:

  • In the event of overdosage, the prescribing information requires the discontinuation of the medication.
  • Treatment for overdosage is mandated to be symptomatic and require the institution of supportive measures.
  • No specific antidote is known for Sarecycline overdose documented in the official regulatory prescribing information.
  • Government guidance explicitly states that immediate medical attention is required by contacting emergency services or a Poison Control center.

Connection to the overall overdose profile

The regulatory profile for Sarecycline overdose is established by the mandatory procedural instructions for management, which include the immediate discontinuation of the drug and the provision of symptomatic and supportive measures. This structure emphasizes that any suspected overdose scenario requires external medical intervention to initiate the official supportive care procedures.

Therapeutic Uses of Seysara

Quick Facts: Seysara Uses

  • Condition Addressed: Moderate to severe acne vulgaris, specifically inflammatory lesions that are non-nodular.
  • Approved Patient Group: Individuals 9 years of age and older.
  • Therapeutic Role: Helps manage symptoms associated with the approved condition.

Seysara (sarecycline) is used for the management of inflammatory lesions associated with non-nodular moderate to severe acne vulgaris. This medication is for use in patients beginning at 9 years of age and older. Its primary function is to help address the symptoms of acne in the specified severity range.

The use of Seysara has been evaluated for up to 12 weeks for its ability to help achieve an improved Investigator's Global Assessment (IGA) score, which is a measure of acne severity, and to help reduce the count of inflammatory lesions. The benefit and safety of using this product beyond 12 weeks for effectiveness and 12 months for safety have not been established.

Eligibility and Restrictions for Use

The official regulatory profile for Seysara defines eligibility strictly based on age, allergy, and physiological status. The medicine is contraindicated and must not be used in several defined populations.

Eligibility Status Population Group Regulatory Basis
Contraindicated Known hypersensitivity to any tetracycline-class drug. Absolute exclusion for allergy.
Contraindicated Children under 9 years of age. Risk of permanent tooth discoloration.
Contraindicated Pregnant women. Potential for fetal harm.

Seysara is approved for use in individuals 9 years of age and older. While use is generally permitted in patients with mild to severe renal impairment or mild to moderate hepatic impairment, other groups have restrictions. Breastfeeding is not recommended due to the potential for adverse effects on the nursing infant's bone and tooth development.

Furthermore, use is not established in geriatric patients aged 65 and older or in those with severe hepatic impairment, as clinical studies have not provided sufficient data for these specific populations. Eligibility classifications are defined exclusively by official regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Seysara (sarecycline) interaction patterns are defined by specific regulatory constraints, primarily concerning pharmacodynamic effects and altered drug exposure.

Co-administration with oral retinoids (such as isotretinoin or acitretin) is avoided due to the official, documented risk of an additive effect that may lead to increased intracranial pressure (pseudotumor cerebri). Furthermore, simultaneous use with penicillin-class antibiotics should be avoided as the tetracycline class may interfere with the intended bactericidal action of penicillin.

A major pharmacokinetic interaction requires mandatory dose timing separation. Substances containing divalent or trivalent cations, including antacids, iron-containing preparations, and bismuth subsalicylate, must be administered separately from sarecycline. This separation is necessary because these products impair the absorption of sarecycline in the gastrointestinal tract, leading to decreased systemic exposure and potential loss of effectiveness.

Sarecycline is officially documented as a P-glycoprotein (P-gp) inhibitor. This means co-administration can increase the plasma concentration of sensitive P-gp substrate medicines, such as digoxin, requiring clinical monitoring. Furthermore, a pharmacodynamic interaction is noted with anticoagulants (like warfarin), as the drug class may depress plasma prothrombin activity, potentially increasing the risk of bleeding. The regulatory profile confirms no clinically significant difference in the drug’s exposure in patients with renal impairment or mild to moderate hepatic impairment.

Mechanism of Action

How Seysara Works


Targeted Inhibition of Bacterial Protein Synthesis

The primary mechanism involves the molecule acting as a specific inhibitor by binding to the bacterial 30S ribosomal subunit. This molecular interaction halts the production of proteins essential for growth and replication, resulting in a bacteriostatic effect and a reduction in the population density of susceptible bacteria .


Modulation of Host Inflammatory Mediators

Separate from its antibacterial action, the molecule exerts a modulatory effect by interfering with host cellular pathways. This action suppresses the release of key pro-inflammatory cytokines and tissue-degrading enzymes (Matrix Metalloproteinases or MMPs), which contributes to the modulation of localized inflammatory signaling and a reduction of subsequent tissue changes.


The drug's structure is optimized for a narrow-spectrum activity, primarily targeting specific Gram-positive bacteria. The molecular action of halting bacterial protein synthesis reduces the bacterial load, which is a physiological stimulus for inflammatory signaling. Independent of this action, the modulatory effect on host mediators further attenuates the physiological changes associated with inflammation. This dual-action mechanism targeting both the microbiological component and the resulting host response defines the drug’s physiological mechanism profile.

Dosage and Administration Information

How Seysara is Used: Administration Guidelines

Seysara (sarecycline) is an oral medication prescribed in the form of film-coated tablets, available in 60 mg, 100 mg, and 150 mg strengths. The primary administration protocol is structured around a once-daily schedule and is dictated by the patient's body weight, resulting in a standardized dose across the population of individuals 9 years of age and older.


Dosage Schedule and Intake Conditions

The required daily strength is based on the following weight brackets, and the once-daily frequency is the standard application:

Patient Weight Range Required Daily Dose
33–54 kg 60 mg
55–84 kg 100 mg
85–136 kg 150 mg

Administration is flexible concerning meals, as the tablet may be taken with or without food. However, to facilitate proper swallowing and reduce the practical potential for esophageal irritation, each dose is ingested with adequate amounts of fluid, such as water.


Duration and Specific Rules

The usage protocol is typically established for a defined period, with efficacy generally evaluated over a course of up to 12 weeks. If no adequate clinical improvement is observed after this duration, the continued treatment protocol requires reassessment. For a missed dose, the standard procedure is to take it as soon as possible unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped; two doses are not to be taken close together. No dosage adjustment is necessary for patients with mild, moderate, or severe renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Seysara (Sarecycline)

Research into sarecycline was primarily established using two large, controlled clinical trials. These studies were randomized and double-blind, meaning participants were assigned to the medicine or an inactive substitute (placebo) by chance. These studies examined symptom patterns in individuals from 9 to 45 years of age diagnosed with facial acne characterized as moderate to severe.

The primary assessment period in these short-term studies covered 12 weeks. Outcomes related to symptom intensity were tracked, including changes in the overall acne severity score (Investigator’s Global Assessment or IGA) and the count of inflammatory lesions. Evidence contributes to understanding symptom patterns observed during the 12-week study period.

For the body, post-hoc analyses explored the association of sarecycline with truncal acne outcomes, examining outcomes related to overall severity scores for lesions on the chest and back. However, these analyses represented secondary or exploratory measurements, meaning the primary research goal was not directed specifically at truncal acne.

Long-term observation was conducted in open-label extension studies for up to 12 months of continuous use. The primary objective was to monitor outcomes over a longer duration. Because they did not use a placebo or another active drug for comparison, comparative evidence is lacking regarding the long-term outcomes after the initial 12-week controlled phase. Long-term effects are not fully established beyond the one-year follow-up period.

Research specifically included children starting at 9 years of age. Conversely, evidence for older adults (individuals aged 65 and over) remains insufficient. Furthermore, comparative evidence is lacking against other oral tetracycline-class antibiotics. The study populations generally excluded patients presenting with the most extreme forms, specifically nodular or cystic acne.

Key Studies & References Sarecycline for the Treatment of Moderate to Severe Acne Vulgaris: Safety and Efficacy Results from Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials

Frequently Asked Questions (FAQ)

Common questions about Seysara (FAQ)

Q: What kind of acne does Seysara (sarecycline) treat?

A: Regulatory documents indicate that the medicine is specifically approved for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. This means its official use is limited to certain types of inflammatory acne in patients 9 years of age and older.


Q: Is Seysara used to treat conditions other than acne?

A: Official labeling for this drug states that it has not been evaluated in the treatment of infections other than acne vulgaris. The safety and efficacy of the drug are not established for use beyond its approved indication.


Q: Does Seysara work for chest and back acne as well as facial acne?

A: The primary official indication is for acne vulgaris, based on studies that assessed efficacy on facial acne. While clinical trial data related to truncal acne (chest and back lesions) were also explored, the drug is officially indicated for acne vulgaris in general.


Q: How quickly does Seysara start to work for acne?

A: Information from clinical trials indicates that a statistically significant reduction in inflammatory lesion counts began as early as Week 3 of the 12-week treatment period. Ongoing improvements were generally tracked throughout the rest of the study duration.


Q: Is sun sensitivity a major concern when taking Seysara?

A: Like other medicines in the tetracycline class, the drug carries a warning for photosensitivity, which means an exaggerated sunburn reaction may occur. The official product information advises minimizing or avoiding exposure to natural or artificial sunlight (such as tanning beds) and wearing protective clothing.


Q: Can Seysara cause permanent tooth discoloration?

A: The use of the drug during periods of tooth development—specifically the second and third trimesters of pregnancy, infancy, and childhood up to the age of 8 years—may cause permanent discoloration of the teeth (yellow-gray-brown). No specific risk of permanent discoloration is highlighted for adults whose teeth are fully formed.


Q: Does Seysara affect my body's natural gut bacteria compared to other antibiotics?

A: The drug is described as a narrow spectrum antimicrobial agent, meaning it targets a more specific range of bacteria, primarily those associated with acne. Official documents state that the narrow spectrum is a differentiating factor, but they do not provide a direct comparison on its precise effect on the overall gut microbiome compared to other antibiotics.


Q: Can Seysara cause symptoms like a spinning sensation (vertigo)?

A: As a tetracycline-class drug, central nervous system side effects have been reported, including dizziness or a spinning sensation called vertigo. Official product information notes that these symptoms may disappear during therapy or when the drug is discontinued.


Q: Does Seysara affect fertility in males or females?

A: Official warnings state that the drug may cause fertility problems in males. This may affect the ability to father a child. The labeling does not contain specific information about effects on female fertility, but it is contraindicated in pregnancy.


Q: Are there any long-term safety studies available for Seysara?

A: The official product information specifies that the efficacy of the drug has not been established beyond 12 weeks, and its safety profile has not been established beyond 12 months of use in studies.


Q: Does Seysara have anti-inflammatory properties?

A: Yes, pharmacological studies have demonstrated the drug has an anti-inflammatory effect in vitro, which is separate from its primary action of inhibiting bacterial protein production.


Q: Is Seysara safe to use during pregnancy or while breastfeeding?

A: The drug is contraindicated in pregnancy due to the potential for fetal harm, including tooth discoloration and inhibition of bone growth. Breastfeeding is not recommended due to the potential for adverse effects on the nursing infant's bone and tooth development.


Q: Does Seysara cause changes in vision, such as blurry vision?

A: Clinical signs of a serious adverse reaction known as Intracranial Hypertension (increased pressure in the skull) can include headache, blurred vision, and other vision changes.


Q: Why is it important to use Seysara only as prescribed?

A: Regulatory documents emphasize that the drug should be used only as indicated to help reduce the development of drug-resistant bacteria. This practice helps maintain the effectiveness of this and other antibacterial drugs.


Q: Can a person take Seysara if they are allergic to other tetracycline drugs?

A: The drug is contraindicated and should not be used by persons who have shown hypersensitivity to any drug in the tetracycline-class due to the risk of serious allergic reactions.


Q: Why should Seysara be taken with a full glass of water?

A: The official instruction for administration is to ingest the tablet with adequate amounts of fluid (such as water). This is done to help reduce the risk of esophageal irritation and ulceration in the throat and esophagus.


Q: Can Seysara cause severe diarrhea, such as C. difficile-associated diarrhea?

A: Clostridioides difficile-associated diarrhea (CDAD) is listed as a serious adverse reaction reported with nearly all antibacterial agents. This condition may range in severity from mild diarrhea to fatal colitis.


Q: What is the risk of developing a yeast infection when using Seysara?

A: As with other antibiotics, the use of the drug may result in the overgrowth of non-susceptible organisms, including fungi. Vaginal yeast infections were reported in less than 1% of women in clinical trials.


Q: Is it known whether Seysara can cause liver issues?

A: Official labeling lists increased liver enzymes (ALT, AST) as an uncommon adverse reaction. The effect of severe liver impairment on the drug's metabolism has not been fully assessed in studies.


Q: Are there specific instructions for storing Seysara tablets?

A: The tablets must be stored at Controlled Room Temperature, specifically 20 C to 25 C (68 F to 77 F). The label permits short excursions to 15 C to 30 C (59 F to 86 F), and the medication must be protected from moisture and excessive heat.


Q: Can Seysara cause stomach pain or nausea that is severe?

A: Nausea, vomiting, and abdominal pain are listed as common side effects. While these are usually mild, more severe gastrointestinal reactions, such as C. difficile-associated diarrhea, are officially documented as serious risks.


Q: Is it common to have headaches when first starting Seysara?

A: Headache is listed as a common adverse reaction in clinical trials (ge 1% incidence). Official information notes that central nervous system side effects may disappear during therapy or when the drug is stopped.


Q: What conditions make a person ineligible to take Seysara?

A: The official product labeling lists several contraindications (reasons the drug must not be used). These include a known hypersensitivity to any tetracycline-class drug, use in pregnant women, and use in children under 9 years of age.


Q: What happens if I miss a dose of Seysara?

A: The official instruction for a missed dose is to take it as soon as possible, unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped; patients must not take two doses close together.

How should Seysara be stored and disposed of?

How to Store and Dispose of Seysara

Seysara (sarecycline) tablets require storage at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F), with limited excursions allowed. The medication must be protected from environmental factors; specifically, it must be kept away from excess heat and moisture and should not be frozen.

Container and Child Safety

  • The tablets must remain in the container it came in and the container must be kept tightly closed.
  • Seysara must be stored out of the sight and reach of children.

Disposal

Unused or expired Seysara must be disposed of according to local requirements, preferably through a designated medicine take-back program. If take-back is unavailable, the tablets should be mixed with an unappealing substance, sealed in a bag, and placed in the trash; the medicine must not be flushed down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Seysara found in:

A-Z Index: